Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153881 · ClinicalTrials.gov registry record · Phase 1
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
A Phase 1 study of Esophageal Neoplasms, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00153881 is a Phase 1 study of Esophageal Neoplasms that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 44 participants, below the 1,485-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00153881, a Phase 1 study of Esophageal Neoplasms, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
Conditions Studied
Interventions
- DRUG Capecitabine (Xeloda)
Study Locations (1)
New Hampshire
- Norris Cotton Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153881
The ClinicalTrials.gov registry entry for NCT00153881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,485-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Capecitabine (Xeloda) is the first listed.
NCT00153881 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00153881 about?
NCT00153881 is a clinical study titled "Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer". The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
What is the current status of trial NCT00153881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2000-02. Estimated completion is 2013-09.
What conditions does trial NCT00153881 study?
This clinical trial studies the following conditions: Esophageal Neoplasms.
What interventions are being tested in trial NCT00153881?
The interventions under investigation include: Capecitabine (Xeloda) (DRUG).
Who is sponsoring clinical trial NCT00153881?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00153881 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.